Skip to main content
Diane Simeone, MD, General Surgery, La Jolla, CA

DianeMSimeoneMD

General Surgery La Jolla, CA

Pancreas, Surgical Oncology (Other than Breast), Minimally Invasive Surgery

Director, Pancreatic Cancer Center at NYU Langone Health; Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery; Professor, Department of Pathology; Associate Director, Translational Research, Perlmutter Cancer Center

Dr. Simeone is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Simeone's full profile

Already have an account?

  • Office

    3855 Health Sciences Dr
    La Jolla, CA 92093
    Phone+1 800-926-8273

Summary

  • Dr. Diane Simeone is the Laura and Isaac Professor of Surgery and Pathology at New York University and the Director of the Pancreatic Cancer Center. She also serves as the Associate Director for Translational Research for the Perlmutter Cancer Center at NYU. An internationally renowned pancreatic surgeon and researcher with a long-standing career focus on the treatment of pancreatic cancer and pancreatic cystic tumors, she has performed over 1000 pancreatic resections using state-of-the art techniques. She has been an innovator in the development of therapeutic clinical trials for pancreatic cancer, and along with her team runs a large clinical research program dedicated to developing an early detection blood test for pancreatic cancer. She is currently the principal investigator of Precision Promise, an exciting new national clinical trials consortium focused on next-generation clinical trials for patients with pancreatic cancer. Dr. Simeone has published more than 175 studies in leading peer-reviewed journals and currently serves as the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and is a member of the scientific advisory board for Let’s Win (Sharing Science Solutions for Pancreatic Cancer). She has previously served as the president of the Society of University Surgeons and the American Pancreatic Association. Dr. Simeone is a member of the Institute of Medicine of the National Academy of Sciences and the National Cancer Institute’s Pancreatic Cancer Task Force.

Education & Training

  • University of Michigan Ross School of Business
    University of Michigan Ross School of BusinessCertified Professional Innovator Program, Scientific Innovation, 2015 - 2015
  • University of Michigan
    University of MichiganResidency, Surgery, 1988 - 1995
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1988

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • CA State Medical License
    CA State Medical License 2024 - 2026
  • MI State Medical License
    MI State Medical License 1991 - 2025
  • CT State Medical License
    CT State Medical License 2022 - 2024
  • NY State Medical License
    NY State Medical License 2017 - 2024
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • America's Top Doctors for Cancer Castle Connolly, 2009-2014, 2016, 2105
  • Chair, Scientific and Medical Advisory Board Pancreatic Cancer Action Network, 2017
  • America's Top Doctors Castle Connolly, 2009-2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Tunable Thermal‐Sensitive Polymer–Graphene Oxide Composite for Efficient Capture and Release of Viable Circulating Tumor Cells  
    Diane M Simeone, Monika L Burness, Max S Wicha, Advanced Materials

Lectures

  • Adaptive Platform Trial Design: The New Horizon for Pancreas and Other Cancers 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020

Press Mentions

  • Study: Breast Cancer Drug Shows Potential for Rare Appendix Cancer
    Study: Breast Cancer Drug Shows Potential for Rare Appendix CancerOctober 16th, 2024
  • Immunovia Has Successfully Acquired All Blood Samples Required to Clinically Validate Its Next-Generation Test for Pancreatic Cancer
    Immunovia Has Successfully Acquired All Blood Samples Required to Clinically Validate Its Next-Generation Test for Pancreatic CancerOctober 7th, 2024
  • Breaking Barriers, Shattering Glass: Women in Medicine Month
    Breaking Barriers, Shattering Glass: Women in Medicine MonthSeptember 25th, 2024
  • Join now to see all

Grant Support

  • Precision Promise National Clinical Trial ConsortiumPancreatic Cancer Action Network2016–2021
  • Prospective Study of the IMMray PanCan-d Test for the Early Detection of Pancreatic CancerImmunovia2016–2020
  • ATDC Function in Human Pancreatic AdenocarcinomaNIH R012015–2020
  • Oncogenic Function of ATDC in Bladder CancerNIH R012014–2019
  • development of a Robust Family History Tool for Pancreatic CancerRolfe Foundation2017–2018
  • CTC Personalized TherapeuticsLustgarten Foundation2015–2018

Research History

  • Associate Director for Translational Research, Perlmutter Cancer CenterI guide translational research development in different disease groups in the cancer center to enhance translational and clinical rollout of impactful scientific findings2017 - 2025
  • Director, Pancreatic Cancer CenterI direct the research development from basic, translational to clinical for pancreatic cancer at the institution2017 - 2025

Professional Memberships